We tested the influence of IFNg on proteasome activity in parental Hep G2 cells that do not metabolize ethanol, as well as in recombinant Hep G2-derived cells that express either or both alcohol dehydrogenase (ADH) and cytochrome P4502E1 (CYP2E1). IFNg treatment increased proteasome activity in VL-17A (ADH þ , CYP2E1 þ ) and E-47 (CYP2E1 þ ) cells, but not in Hep G2, VI-R2 (parental cells with empty vectors) or in VA-13 (ADH þ ) cells. Proteasome activation by IFNg correlated positively with the level of CYP2E1 activity. Treatment of VL-17A cells with agents that inhibit CYP2E1 or the inducible nitric oxide synthase (iNOS) or that prevent the formation of peroxynitrite also blocked proteasome activation by IFNg, indicating that the proteasome may be directly activated by products of CYP2E1 and iNOS catalysis. While IFNg treatment increased proteasome activity, it also decreased CYP2E1 activity. Both effects were mediated via the Janus kinase-signal transducer and activator of transcription 1 (JAK-STAT1) pathway, as both were blocked by the JAK2 inhibitor, tyrphostin AG 490. Ethanol treatment of VL-17A cells also caused a similar blockage of these same IFNg-mediated effects, by inhibiting STAT1 phosphorylation. This inhibition was largely due to ethanol metabolism, as 4-methylpyrazole, an ethanol metabolism inhibitor, restored IFNg-mediated STAT1 phosphorylation in ethanol-treated cells. Our results lead us to propose that IFNg initiates signal transduction, which alters the activities of CYP2E1 and iNOS, thereby producing reactive oxygen species. One of these oxidants, possibly peroxynitrite, may be directly involved in proteasome activation. Ethanol metabolism by VL-17A cells suppresses IFNg-mediated induction of proteasome activity, in part, by preventing STAT1 phosphorylation. #
Introduction
The proteasome is a large proteolytic particle that contains multiple catalytic activities for protein degradation. The proteasome participates in the regulation of normal physiological processes in cells, by degrading short-lived regulatory proteins that have roles in vital cellular functions including proliferation and apoptosis, as well as degrading long-lived constitutive enzymes. The proteasome also has an important role in cellular defense by degrading damaged, potentially cytotoxic proteins [1] [2] [3] [4] . Thus, the proteasome is vital for many important cell functions [5, 6] . The enzyme particle is also involved in antigen presentation [7] . The specific subunits of the immunoproteasome, cleave proteins to distinct peptides, which form complexes with major histocompatibility complex (MHC) class I molecules on the cell surface. These complexes can be recognized by cytotoxic T-lymphocytes (CTLs) that eliminate target cells with foreign peptide repertoires [8] . Any MHC class I þ host cell, including the hepatocyte, may be targeted by CTLs [9, 10] . The liver is the primary site of ethanol oxidation, and this organ sustains significant damage from chronic ethanol consumption [11] . In vitro studies using Hep G2-derived cells have demonstrated that ethanol-induced cytotoxicity depends on the levels of expression of the ethanol-metabolizing enzymes, CYP2E1 or ADH [12, 13] and therefore, on the levels of ethanol oxidation. There is evidence that metabolites generated from ethanol oxidation can exert inhibitory effects on a number of cellular pathways including the activity of the proteasome. In hepatocytes of patients with alcohol-induced liver disease, Mallory bodies are typical histological hallmarks [14] . These are believed to form as a result of compromised proteasome function or even proteasome depletion [15] . Ethanol consumption can cause reduced hepatic proteasome activity. This effect is associated with high blood ethanol levels in vivo when ethanol is administered by continuous intragastric feeding, which, also results in increased hepatic lipid peroxidation (oxidative stress) [16, 17] . Impaired proteasome function appears to result from ethanol metabolism [18] . Pro-inflammatory cytokines, including IFNg, are natural modulators of proteasome activity [19] . IFNg acts on a cell by binding to surface IFNg receptors, which initiate the transduction of signals to nuclear genes via the JAK-STAT1 pathway. This occurs by phosphorylation of STAT1, which is then translocated to the nucleus and binds to DNA, initiating downstream effects, which include the modulation of proteasome function in antigen-presenting cells, such as macrophages and dendritic cells [20, 21] . However, the effect of IFNg on proteasome activity in liver cells has not been characterized.
The aim of this work was to study the response of the proteasome to IFNg and the transduction of IFNg signals in recombinant Hep G2 cells incubated in the presence or absence of ethanol. We tested the influence of IFNg on proteasome chymotrypsin-like activity in parental Hep G2 cells that do not metabolize ethanol, as well as in recombinant Hep G2-derived cells that express either or both ADH and CYP2E1. We also determined whether ethanol itself or the products of its metabolism altered the responsiveness of the proteasome to IFNg. We found that IFNg treatment enhanced proteasome activity via the JAK-STAT1 pathway and that this enhancement occurred only in CYP2E1-expressing cells. Here, we provide evidence that this effect may be mediated by peroxynitrite. We further show that prior exposure of cells to ethanol prevented the IFNg-induced increase in proteasome activity by blocking STAT1 phosphorylation. Portions of this work have been described in recent abstracts [22, 23] .
Materials and methods

Reagents and media
High glucose Dulbecco's modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen. The membrane-permeable flourogenic proteasome substrate, methoxysuccinyl-phe-leu-phe-7-amido-4-trifluoromethyl coumarin (FLF-AFC) was obtained from Enzyme Systems Products. Human recombinant IFNg was from PeproTech, Inc. Anti-IFNgRa was from PharMingen. The antibody preparations to phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and STAT1 were from Cell Signaling and from Santa Cruz Biotechnology, Inc., respectively. Diallyl sulfide (DAS), tyrphostin AG 490, and succinyl-Leu-Leu-ValTyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) were purchased from Sigma. N,o-Nitro-L-arginine methyl ester (L-NAME), epigallocatechin gallate (EGCG), and 6,10,15,20 tetrakis(4-sulfonatophenyl) porphyrinato iron (III) chloride (FeTPPS) were from Calbiochem. All other chemicals used were analytical grade quality.
Cell lines
All cell lines were derived from the human hepatoblastoma cell line Hep G2, which were obtained from the American Type Culture Collection. Cells expressing both ADH and CYP2E1 were developed by transfecting VA-13 (ADH þ ) cells with the expression vector pIV-G2. This vector contains the coding region of the human cytochrome P4502E1 gene. The coding region was kindly provided by Dr. Frank Gonzalez (National Cancer Institute). VA-13 cells were transfected using Lipo TAXI (Invitrogen Corp.) as described by the manufacturer. Recombinant cells were selected in culture medium containing G418 and zeocin, each at 400 mg/mL. Clones were isolated, and clonal cell lines established. Clones were expanded and screened for ADH and CYP2E1 activity. One of the resulting clones, designated VL-17A, was used in the present study. These cells were phenotypically identical to VA-13 cells [12] in their ability to metabolize ethanol and generate acetaldehyde, but they also express CYP2E1 at levels that are comparable to those of rat hepatocytes [24] . 1 As a control cell line, Hep G2 cells were transfected with both empty vectors, pcDNA3.1 and pcDNA3.1/Zeo (þ) (Invitrogen). These transfected cells were designated VI-R2 cells. CYP2E1-expressing E-47 cells were the kind gift of Dr. A. Cederbaum (Mount Sinai School of Medicine).
Alcohol dehydrogenase (ADH) activity
Cells were washed with phosphate-buffered saline (PBS) and then detached from the plastic by treating with trypsin. Dislodged cells were resuspended in PBS and lysed by sonication. Each lysate was centrifuged at low speed to remove cell debris, and the supernatant was centrifuged for 1 hr at 105,000 g to sediment the microsome fraction. The supernatant (cytosol) was removed and supplemented with glycerol to a final concentration of 20% (v/v). ADH activity in the cytosolic fraction was measured as originally described by Crow et al. [25] and modified by Clemens et al. [26] and normalized for protein concentration. One ADH enzyme unit catalyzed the formation of 1 nmol of NADH (nicotinamide adenine dinucleotide, reduced form) per hour. Specific activity is expressed as units per mg protein.
CYP2E1 catalytic activity
The microsome pellet derived from the 105,000 g centrifugation was re-suspended in 250 mL PBS containing 20% glycerol. CYP2E1 activity was measured by hydroxylation of p-nitrophenol, as described originally by Koop [27] and modified by Chen et al. [28] . In this micro-assay, the mixture had a final volume of 100 mL and was incubated for 1 hr. Formation of 4-nitrocatechol (4-NC), the reaction product, was measured by absorbance at 515 nm. This was compared to the absorbance obtained using known quantities of 4-nitrocatechol (4-NC). One CYP2E1 enzyme unit catalyzed the formation of 1 nmol 4-NC/hr. Specific activity is expressed as units per mg protein.
Protein concentration was measured by the dye binding technique of Bradford [29] using reagents from Bio Rad.
In situ proteasome assay
The chymotrypsin-like activity of the proteasome was measured by FLF-AFC hydrolysis, which was determined by a modification of the method described previously [30] . Briefly, cells were plated into 24-well plates at a density of 1 Â 10 5 cells/well in DMEM supplemented with appropriate antibiotics and 10% FBS. After 24 hr of incubation, the medium was replaced with DMEM containing 3% FBS and 25 mM HEPES. For experiments using ethanol, plates were sealed with adhesive sealing films for micro-plates (ThermalSeal TM , Excel Scientific) to prevent ethanol evaporation. After 72 hr incubation at 378, the medium was replaced with serum-free DMEM containing 13 mM FLF-AFC. Fluorescence of AFC was measured every 2 hr on a Fluorolite 1000 plate reader (Dynex Technologies) using excitation and emission filter settings of 390 and 530 nm, respectively. After the last reading, the attached cells were lysed by direct sonication of each well, and samples were taken for the fluorometric measurement of DNA [31] , which was used for normalization. Data are expressed as nmole AFC/mg DNA. Nanomoles of AFC were calculated on the basis of an AFC standard curve. To determine the specificity of proteasome activity with FLF-AFC, cells were treated with 10 mM lactacystin, a specific proteasome inhibitor, which caused a 70% decline in the rate of FLF-AFC hydrolysis (data not shown).
In vitro proteasome assay
For in vitro measurements of chymotrypsin-like activity of the proteasome, cells were lysed by sonication in PBS.
Suc-LLVY-AMC hydrolysis using cytosolic fractions of the lysates was tested as described by Donohue et al. [16] .
Exposure of cells to IFNg
In most cases, cells were exposed to IFNg (10 ng/mL), for 24 hr. In some dose-response and kinetic experiments, the concentration of IFNg varied from 2 to 50 ng/mL, and the duration of treatment varied between 0 and 24 hr.
Detection of interferon gamma receptor alpha (IFNgRa)
To determine the relative levels of IFNgRa, cells were plated onto 6-well plates at 1 Â 10 6 cells/well in DMEM supplemented with 3% FBS, 25 mM HEPES and ethanol (0 or 100 mM). After incubation for 72 hr, cells were washed with PBS and detached from the plate using Cellstripper (Cellgro), centrifuged, washed and suspended in blocking buffer (PBS containing 0.1% sodium azide and 3% FBS) for 15 min to prevent non-specific binding of protein. Cells (1 Â 10 6 /tube) were incubated in 100 mL for 30 min on ice with 1 mg of phycoerythrin-conjugated antihuman IFNgRa (PharMingen) and then washed twice in cold PBS. As an isotype control, anti-human IgG-PE antibody (PharMingen), was used. The cells were analyzed with a FACSCAN flow cytometer (Becton Dickinson) to detect bound antibody.
Detection of STAT1 and phospho-STAT1
Cells were plated onto 6-well plates using DMEM with 10% FBS. After overnight attachment at 378, the medium was changed to serum-free DMEM with or without 100 mM ethanol, and cells were incubated for 72 hr. Cells were treated or not with IFNg (10 ng/mL), for 1, 5 or 24 hr. Then, cells were lysed by freezing and thawing using 0.5 mL of lysis buffer (40 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 100 mM sodium fluoride, 1% Triton X-100, 2 mg aprotinin/mL). A portion of each lysate (30 mg protein/well) was subjected to SDS-PAGE on 12% gels. Proteins were electrophoretically transferred onto nitrocellulose membranes. Membranes were blocked with 5% bovine serum albumin (BSA) for 1 hr at room temperature and then incubated overnight at 48 with anti-phospho-STAT1 (pSTAT1), diluted 1:1000. The membranes were extensively washed with Tris-buffered saline containing 0.1% Tween 20 (TBS-T), exposed to 5000-fold diluted peroxidase-conjugated, goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.), washed and visualized by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech). The same membranes were then stripped for 30 min at 508 in 62.5 mM Tris-HCl pH 6.7, 100 mM 2-mecaptoethanol, 2% sodium dodecyl sulfate. They were re-blocked in 5% dry non-fat milk-TBS-T overnight at 48 and exposed to anti-STAT1 (1:1000) antibodies for 1 hr at room temperature. Subsequently, the membranes were incubated with peroxidase-conjugated secondary antibodies (1:2000) and visualized by ECL. The bands were quantified by densitometry, and the pSTAT1/STAT1 densitometric ratio was calculated.
Statistical analyses
Data are expressed as mean values AE standard deviation. Because the analyzed parameters had a normal distribution, comparisons for significance were determined by Student's t-test between two groups or by one-way ANOVA, using a Tukey post-test for multiple comparisons. For correlations, Pearson's coefficient of correlation was used. A probability value of 0.05 or less was considered significant.
Results
To determine whether IFNg affects the activity of the proteasome, we treated VL-17A and VI-R2 and/or Hep G2 cells with various doses of IFNg (2-50 ng/mL) for 1-24 hr. Chymotrypsin-like activity of the proteasome was subsequently tested in situ by FLF-AFC hydrolysis. Exposure to IFNg increased FLF-AFC hydrolysis by 20-50% in VL-17A cells compared with their untreated controls. This increase was first detected after 4 hr of treatment with IFNg and remained elevated after 24 hr (Fig. 1A) . Proteasome activity in cell lysates or the cytosolic fractions of VL-17A cells assayed in vitro with Suc-LLVY-AMC was increased up to 40% after treatment with IFNg (not shown). However, proteasome activity in VI-R2 and Hep G2, both ethanol non-metabolizing cells, did not increase in response to IFNg treatment regardless of IFNg dose and time of treatment (Fig. 1B, D and E) . We examined whether ethanol influenced the activation of the proteasome by IFNg. VL-17A and VI-R2 cells were each treated with 0, 25, 50 and 100 mM ethanol for 72 hr and then exposed to IFNg. Ethanol alone, at all concentrations, had no effect on proteasome activity in Hep G2 cells (not shown), or in VI-R2 cells (data shown in Fig. 2, panel  B) . However, 100 mM ethanol treatment caused a 30-40% decrease in proteasome chymotrypsin-like activity in VL-17A cells compared with their untreated controls. Additionally, in VL-17A cells, ethanol, at even lower concentrations (25 and 50 mM) that, by themselves, did not significantly affect FLF-AFC hydrolysis, prevented proteasome activation by IFNg (Fig. 2) .
The unresponsiveness of Hep G2 and VI-R2 cells to IFNg (Fig 1B, D and E) was not due to reduced levels or the absence of IFNg receptors on these cells. Flow cytometric analyses revealed that both VI-R2 and VL-17A cells had comparable numbers of IFNgR-positive cells. Non-specific staining with isotype-specific antibodies occurred in less than 0.5% of cells. Furthermore, there was no indication that treatment with 100 mM ethanol for 72 hr reduced IFNgR levels in either cell type (Fig. 3) .
Because proteasome activity was enhanced by IFNg in VL-17A but not in VI-R2 or Hep G2 cells, we tested the possibility that ADH and/or CYP2E1 expression may be involved in IFNg-induced activation of the proteasome. We treated ADH-expressing VA-13 cells and CYP2E1-expressing E-47 cells with IFNg for 24 hr. IFNg treatment enhanced proteasome activity in E-47 cells by 20% (P ¼ 0:05), but it caused no change in proteasome activity in VA-13 cells (Fig. 4) , indicating that the IFNg-mediated elevation of proteasome activity was related to CYP2E1, but not to ADH expression.
CYP2E1 activity in VL-17A cells was not constant in all experiments. Enzyme activity varied as much as 2-fold between passages. We noted that the magnitude of proteasome activation by IFNg was positively associated with the basal CYP2E1 activity of VL-17A cells before treatment with the cytokine. Statistical determination of such a correlation indeed showed that VL-17A cells with higher CYP2E1 activity had a greater degree of proteasome activation with IFNg than those with lower CYP2E1 activity (Pearson r ¼ 0:9389, P ¼ 0:0055). Conversely, pretreatment of cells with 10 mM diallyl sulfide (DAS), an inhibitor of CYP2E1 catalytic activity [32] , prevented proteasome activation by IFNg (Fig. 5) . These data indicate that a product of CYP2E1 catalysis may have a role in proteasome activation following treatment with IFNg.
IFNg also increases iNOS activity, which results in the increased production of nitric oxide (NO) [33] . To determine the contribution of IFNg-mediated NO formation to proteasome activation, we treated VL-17A cells with IFNg in the presence of the iNOS inhibitors, L-NAME (300 mM) and EGCG (200 mM) for 24 hr. Both agents blocked proteasome activation by IFNg (Fig. 6A and B) . These latter data indicated that NO, in addition to the product derived from CYP2E1 catalysis, participated in IFNgelicited proteasome activation. To test the possibility that peroxyntrite may be the responsible agent, we treated VL-17A cells with IFNg and the peroxynitrite scavenger, FeTPPS (10 mM), which converts peroxynitrite to NO [34] . This compound also prevented proteasome activation by IFNg (Fig. 6C) .
In accordance with previous findings [35] , IFNg treatment of VL-17A cells for 24 hr decreased CYP2E1 activity by 50%. However, exposure of these cells to 100 mM ethanol for 72 hr enhanced CYP2E1 activity up to 5-fold. This effect was slightly, but not significantly attenuated by IFNg (Fig. 7) .
To determine whether CYP2E1 and proteasome activities are regulated by IFNg via the JAK-STAT pathway, we exposed VL-17A cells to IFNg in the presence and absence of the selective JAK2 phosphorylation inhibitor, tyrphostin AG 490. This treatment prevented the enhancement of proteasome activity as well as the decrease of CYP2E1 activity (Fig. 8) , indicating that the JAK-STAT pathway is involved in both these processes.
We further tested the effects of ethanol on the transduction of IFNg signal via the JAK-STAT1 pathway using ethanol-metabolizing VL-17A cells and non-metabolizing Hep G2 cells. During the final 24 hr interval of a 72 hr ethanol exposure, cells were treated or not with IFNg (10 ng/mL), for 0, 1, 5 and 24 hr. Both phosphorylated STAT1 (pSTAT1) and total STAT1 were determined in cell lysates by Western blot. As shown in Fig. 9 , ethanol treatment decreased the pSTAT1/STAT1 ratio in Hep G2 cells by 1.5-2-fold compared with untreated cells after 1 hr of IFNg exposure. By comparison, the pSTAT1/STAT1 (Fig. 10) .
Discussion
The liver is routinely exposed to toxic agents, microbes and viruses arriving via the portal vein from the gastrointestinal tract. Such exposure can activate liver immune cells. Activated intrahepatic lymphocytes secrete IFNg and other cytokines in response to these stimuli, thus putting hepatocytes under continuous cytokine exposure. Hepatocytes abundantly express proteasome activity and previous studies in vivo have shown that IFNg can regulate this activity in liver tissue [36] . However, it is not clear whether IFNg specifically affects proteasome activity in hepatocytes or in intrahepatic immune cells in both. In this investigation, using a liver-derived culture system, we sought to determine whether IFNg altered proteasome activity in cultured recombinant Hep G2 cells, which stably express the ethanol-metabolizing enzymes, CYP2E1 and ADH. Because liver cells are the primary sites of ethanol oxidation, we also explored the possibility that any IFNg modulation of proteasome activity as well as the transduction of IFNg signals in these cells may be altered by ethanol or its metabolism.
In this study, IFNg enhanced proteasome chymotrypsinlike activity in recombinant Hep G2 cells. The kinetics of this response showed an elevation in enzyme activity as early as 4 hr and which remained elevated at the same level 24 hr after exposure to the cytokine. These results indicate that the IFNg-elicited enhancement in enzyme activity was probably not the result of cytokine-induced de novo proteasome synthesis, as the enzyme has a very slow rate of turnover t 1=2 ¼ 12-15 days in rat liver [37] . Rather, the rapidity of this increase in response to IFNg treatment appeared to reflect changes in the activity of the existing enzyme.
Enhancement of proteasome chymotryspin-like activity in Hep G2-derived cells depended upon the expression of CYP2E1 because only VL-17A cells (ADH þ /CYP2E1 þ ) and E-47 cells (CYP2E1 þ ) showed this response to IFNg. Additionally, the degree of IFNg-mediated activation of the proteasomewas positively associated with the basal CYP2E1 activity in VL-17A cells. Furthermore, when we treated the cells with IFNg in the presence of CYP2E1 inhibitor DAS, IFNg no longer increased proteasome activity. Thus, CYP2E1 catalysis was necessary for IFNg-mediated proteasome activation, leading us to suggest that one or more products generated by CYP2E1 influence(s) proteasome activity. It is well known that CYP2E1 is a loosely coupled enzyme that can generate superoxide and other reactive species even in the absence of substrate [38, 39] .
In addition to CYP2E1 catalysis, nitric oxide generation was also required for proteasome activation by IFNg. This was indicated by the blockage of IFNg-mediated proteasome activation by L-NAME and EGCG. Both these agents inhibit NO formation. Furthermore, our time-course experiments (Fig. 1) indicated that proteasome activity began to rise after 4 hr of IFNg treatment. This time period is consistent with that necessary for induction of iNOS by IFNg, previously seen in macrophages [40] . Therefore, we propose that VL-17A cells with higher basal CYP2E1 activities had a greater capacity to produce superoxide from CYP2E1. NO, that was generated by iNOS, following IFNg treatment reacted with superoxide to form peroxynitrite, which, in turn, increased proteasome activity. Furthermore, our results showed that when VL-17A cells were exposed to the peroxynitrite scavenger, FeTPPS, this agent also prevented proteasome activation by the cytokine. These latter findings further uphold our suggestion that the proximal agent responsible for proteasome activation is peroxynitrite.
Peroxynitrite reacts with tyrosine residues in proteins, forming nitrated proteins [41] . Previous studies have shown that mild modification of the enzyme aconitase with low concentrations of peroxynitrite inactivates this enzyme [42] . In light of these and similar findings [43] we thought it unlikely that metabolically derived peroxynitrite would activate the proteasome in VL-17A cells. To test this further, we have recently conducted experiments in vitro, using purified preparations of the 20S proteasome exposed to low concentrations of the peroxynitrite donor 3-morpholinosydnonimine (SIN-1). Compared with untreated enzyme, low SIN-1 concentrations enhanced proteasome chymotrypsin-like activity by as much as 2-fold. However, higher Fig. 8 . The effects of tyrphostin AG 490 on IFNg-mediated effects on CYP2E1 and proteasome in VL-17A cells. Cells were treated or not with 1 mM tyrphostin AG 490 for 1 hr. IFNg (10 ng/mL) was added, and cells were incubated for additional 24 hr. CYP2E1 activity (panel A) was assayed in microsome fractions of cell lysates proteasome activity (panel B) assayed in situ by FLF-AFC hydrolysis. Because of intra-experimental variation in enzyme activity, data are expressed as a percent of untreated control from three independent experiments. Statistical significance was assessed by a mixed effect ANOVA model, in which pair wise comparisons were made among the various treatment groups. Asterisk indicates that the value is significantly different (P < 0:05) from IFNg-treated cells.
concentrations of SIN-1 caused its inactivation. 2 These observations further support our view that peroxynitrite can activate the same catalytic activity of the proteasome that was measured in VL-17A cells, but that such activation is limited and can eventually result in the loss of proteasome activity when the levels of the oxidant become excessive.
In view of these latter observations, it is noteworthy that after 24 hr of IFNg treatment, CYP2E1 activity went down. This IFNg-dependent decrease in CYP2E1 activity confirms the results of earlier studies in hepatocytes showing that IFNg decreases a number of P450 isoenzymes by suppressing their mRNA levels, thereby decreasing their intracellular content [35] . This decrease also occurs at least partly via nitric oxide inhibition of CYP2E1 [44] . Thus, we suggest that in VL-17A cells IFNg-enhances production of NO, which reacts with superoxide to form peroxynitrite. The latter, which is produced at low concentrations, in turn activates the proteasome. At the same time, NO suppresses CYP2E1 catalysis thereby limiting the quantity of superoxide generated by CYP2E1 and thus limiting the degree of proteasome activation.
Proteasome activity declined after treatment of cells with 100 mM ethanol. These results confirm our previous results reported recently and can be attributed to ethanol metabolism, since ethanol-elcited proteasome inactivation can be prevented by inhibition of ethanol metabolism (see Footnote 1). We do not know the mechanism responsible for the decline in proteasome activity, but we speculate that the induced levels of CYP2E1 may generate higher levels of oxidants that contribute to proteasome inactivation. One of these oxidants may indeed be peroxynitrite, as Baraona et al. recently demonstrated that chronic ethanol administration enhances iNOS activity and the formation of peroxynitrite in rat liver [45] .
When cells were exposed to ethanol, neither CYP2E1, nor the proteasome was affected by IFNg. These results indicated that IFNg-mediated effects on CYP2E1 catalysis and proteasome activity were modulated via the same signal transduction pathway. This conclusion is supported by the observed prevention by tyrphostin AG 490 of IFNgmediated proteasome activation and decreased CYP2E1 activity. The results lead us to suggest that the regulation of these enzymes is downstream from JAK-STAT1 signaling.
Exposure of VL-17A cells to 100 mM ethanol prior to IFNg treatment prevented STAT1 phosphorylation in ethanol-metabolizing VL-17A cells. Nguyen et al. [46] reported an impaired IFNg-activated phosphorylation of STAT1 after acute ethanol (30 min) treatment of hepatocytes. However, these authors found no alteration in STAT1 phosphorylation in ethanol-treated Hep G2 or in ADH þ VA-13 cells [47] . They concluded that ethanol-induced suppression of STAT1 phosphorylation could not be attributed to ethanol metabolism. In contrast, our results indicated that during ethanol exposure, VL-17A cells, but not Hep G2 cells exhibited a prominent decrease in STAT1 phosphorylation. Furthermore, the prevention of ethanol metabolism by treatment with 4-MP blocked the ethanolelicited reduction of STAT1 phosphorylation. Thus, we conclude that one or more products of ethanol metabolism blocks IFNg signal transduction in VL-17A cells. Asterisk indicates a significant difference (P < 0:05) in pSTAT1/STAT1 ratio between control and ethanol-treated cells, both exposed to IFNg. Asterisks indicate a significant difference (P < 0:05) in pSTAT1/STAT1 ratio between 4MP-treated and -untreated cells exposed to ethanol and IFNg.
Currently, the identity of those inhibitory products is not clear. In preliminary experiments (not shown) we have observed that ethanol prevents STAT1 phosphorylation in VA-13 cells, but not in E-47 cells, indicating that acetaldehyde has a role in blocking STAT1 phosphorylation. When incubated in the presence of 100 mM ethanol, VL-17A cells generate >200 mM acetaldehyde in the medium. 3 Acetaldehyde is known to activate the protein kinase C (PKC) pathway [48] , which, in turn, down-regulates JAK-STATs [47] . It was recently demonstrated that malondialdehydeacetaldehyde-protein (MAA) adducts also activate the PKC pathway [49] . The formation of these secondary ethanolderived products may also contribute to the ethanol-induced blockade of STAT1 phosphorylation. Thus, these and other mechanisms remain to be investigated.
In Fig. 11 , we present a proposed mechanism of proteasome activation in response to IFNg and how this response may be regulated by ethanol.
In summary, our findings indicate that enhancement of proteasome activity occurred in IFNg-treated Hep G2 cells that express CYP2E1. This enhancement may be related to the production of peroxynitrite, generated by CYP2E1-catalysis (O 2 À ) and the iNOS activity (NO). Both proteasome activity and CYP2E1 activity are regulated by IFNg via the JAK-STAT1 pathway. Ethanol metabolism prevents phosphorylation of STAT1 making the proteasome in VL-17A cells unresponsive to IFNg-mediated effects.
